# S&P Global BMI Index

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/sp-global-bmi-index
Canonical HTML page: https://getfinancebrief.com/entity/sp-global-bmi-index

## Timeline

- **2026-03-15**: Expected Rebalancing — Passive funds expected to complete divestment of RNAM shares to match new index weights.
- **2026-03-03**: S&P Index Deletion — S&P Dow Jones Indices removes RNAM from Global BMI and TMI benchmarks.
- **2026-02-27**: Novartis Deal Closure — Avidity finalizes agreement with Novartis, launching Atrium Therapeutics spinout.

## Recent coverage (1 stories)

### Avidity Biosciences Exits S&P Indices Amid Strategic Shift and Novartis Deal
2026-03-03 02:21:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
Full story: https://getfinancebrief.com/story/avidity-biosciences-rnam-sp-index-deletion-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.